Related Experiment Video
Updated: Nov 21, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Peritoneal melanosis associated with metastatic melanoma previously treated with targeted and immune checkpoint
Kwang Kiat Sim1, Katie Connell2, Mayank Bhandari3
1Department of General Surgery, Fiona Stanley Hospital, Murdoch, Western Australia, Australia kwang.sim@health.wa.gov.au.
Abstract:
Peritoneal melanosis is an uncommon benign condition, the pathophysiology of which is unclear. Macroscopically, it appears as diffuse dark brown or black pigmentation within the peritoneum, mimicking more sinister conditions such as metastatic melanoma. It has been described in a variety of contexts, but only exceedingly rarely in association with metastatic melanoma, with only two previous published case reports. We present a case of peritoneal melanosis associated with metastatic melanoma involving the spleen, previously treated with targeted and immune checkpoint inhibitor therapy. With increasing reports of melanoma regression manifesting as cutaneous tumorous melanosis in patients treated with immune checkpoint inhibitors, we postulate that, similarly, immunotherapy and tumour regression might have a role to play in the pathogenesis of the peritoneal pigmentation in this case.
Insights
Peritoneal melanosis, a rare benign condition, presents as dark peritoneal pigmentation. This case suggests immunotherapy-induced tumor regression may cause peritoneal melanosis in metastatic melanoma patients.
Area of Science:
- Oncology
- Pathology
Background:
- Peritoneal melanosis is a rare benign condition characterized by dark peritoneal pigmentation.
- Its pathophysiology remains unclear, often mimicking metastatic melanoma.
Observation:
- A case of peritoneal melanosis associated with metastatic melanoma involving the spleen is presented.
- The patient had prior treatment with targeted therapy and immune checkpoint inhibitors.
Findings:
- The study explores the potential role of immunotherapy and tumor regression in the pathogenesis of peritoneal melanosis.
- This is only the third reported case linking peritoneal melanosis with metastatic melanoma.
Implications:
- Understanding this association may help differentiate benign peritoneal melanosis from metastatic disease.
- Further research into immunotherapy's effects on peritoneal pigmentation is warranted.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

